DR
David Malcom Rodman (Chief Medical Officer) filed 10 Form 4 reports in the trailing twelve months (0 purchases, 10 sales), most often in Mineralys Therapeutics, Inc. (MLYS). The largest single filing was $9.3M of MLYS (262,752 sh across 3 lots, as filed), executed Jan 2. Data as of Nov 8 2026.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
–
no purchases on file
Delay-adjustediThe same average, entered at disclosure dates
–
returns measure stock purchases only
Filings, ttm
10
0 buys · 10 sells
Median delay
–
measured on stock purchases
Volume, ttmiDollar value disclosed in the trailing twelve months
$13.2M
shares × price, as filed
Last traded
Jul 15
Filed Jul 15
Median ADV $38.0M across their filed names
Open performance→Volume by month
Buys $0
Sells $15.6M
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
10 filings
Sector per market data · by filing · past 12 months
Most traded names
MLYS
Mineralys Therapeutics, Inc.
MLYS · 0 buys · 19 sells
19 filings
Recent filings
MLYSSALE
Mineralys Therapeutics, Inc.
View filing →
$557K20,407 sh across 2 lots
Exec Jul 13
Filed Jul 15 · 8:58 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $350K
14,474 sh across 2 lots
Exec Jun 15
Filed Jun 17 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $152K
6,349 sh × $23.93
Exec Jun 12
Filed Jun 12 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $588K
20,404 sh across 2 lots
Exec May 12
Filed May 13 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $549K
20,406 sh across 2 lots
Exec Apr 13
Filed Apr 15 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $452K
17,074 sh across 2 lots
Exec Mar 12
Filed Mar 16 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $458K
16,342 sh across 3 lots
Exec Feb 12
Filed Feb 13 · 5:30 PM ET MLYSSALE Mineralys Therapeutics, Inc. View filing → $623K
19,076 sh across 2 lots
Exec Jan 13
Filed Jan 15 · 5:30 PM ET More filings →